Epigenetics in Precision Medicine

· Translational Epigenetics 30. knjiga · Elsevier
E-knjiga
614
Broj stranica
Prihvatljiva
Ocjene i recenzije nisu potvrđene  Saznajte više

O ovoj e-knjizi

In recent years, knowledge of epigenetic mechanisms underlying disease onset and progression has proven crucial for the development of novel early diagnosis and prognosis biomarkers for patient stratification and precision medicine. Epigenetics in Precision Medicine, a new volume in the Translational Epigenetics series, provides a thorough discussion and overview of current developments in clinical epigenetics with special emphasis on epigenetic biomarkers that can be used for clinical diagnosis, prognosis, patient stratification, and treatment monitoring. Disease types discussed include cancer, metabolic disorders, neurodegenerative diseases, bone disease, and immune-related disorders. The book examines the challenges of advancing epigenetics research and translating findings to the clinic and drug discovery in each of these areas, as well as current solutions; chapter authors discuss how to leverage epigenomic technologies, applications, and tools, such as next-generation sequencing, to discover new epigenetic biomarkers in disease and drug studies. Epigenetics in Precision Medicine focuses on complex epigenetic mechanisms in several pathologies, and explores how epigenetics can power the advance of precision medicine, not only by improving in vitro diagnostic and prognostic tools, but by providing new therapeutic approaches to treat human disease. - Provides a thorough grounding in epigenetics-driven precision medicine, with emphasis on developing and implementing early diagnosis and prognosis biomarkers, and supporting patient stratification - Empowers researchers and clinicians to incorporate epigenetics in new disease research, drug discovery, and clinical practice - Features chapter contributions from international leaders in the field

O autoru

Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.

Ocijenite ovu e-knjigu

Recite nam šta mislite.

Informacije o čitanju

Pametni telefoni i tableti
Instalirajte aplikaciju Google Play Knjige za Android i iPad/iPhone uređaje. Aplikacija se automatski sinhronizira s vašim računom i omogućava vam čitanje na mreži ili van nje gdje god da se nalazite.
Laptopi i računari
Audio knjige koje su kupljene na Google Playu možete slušati pomoću web preglednika na vašem računaru.
Elektronički čitači i ostali uređaji
Da čitate na e-ink uređajima kao što su Kobo e-čitači, morat ćete preuzeti fajl i prenijeti ga na uređaj. Pratite detaljne upute Centra za pomoć da prenesete fajlove na podržane e-čitače.